CellPro cuts expenditure to cope with litigation
This article was originally published in Clinica
CellPro has carried out an internal reorganisation, including an 11% cut in its workforce, to reduce expenditure as the company defends both a patent litigation battle and a class action lawsuit by investors. The company hopes to reduce its monthly cash burn by around $300,000-500,000 from the present figure of nearly $2 million.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.